<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="https://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="https://www.loc.gov/MARC21/slim https://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="https://www.loc.gov/MARC21/slim">

  <leader>01460nam a2200265   4500</leader>
  <controlfield tag="001">384311</controlfield>
  <datafield tag="010" ind1=" " ind2=" ">
    <subfield code="a">9291681377</subfield>
  </datafield>
  <datafield tag="090" ind1=" " ind2=" ">
    <subfield code="a">384311</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">20070529d2003       y0pory50      ba</subfield>
  </datafield>
  <datafield tag="101" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="200" ind1=" " ind2=" ">
    <subfield code="a">Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs</subfield>
    <subfield code="f">European Monitoring Centre for Drugs and Drug Addiction, EMCDDA</subfield>
  </datafield>
  <datafield tag="210" ind1=" " ind2=" ">
    <subfield code="a">Luxembourg</subfield>
    <subfield code="c">Office for Official Publications of the European Communities</subfield>
    <subfield code="d">2003</subfield>
  </datafield>
  <datafield tag="215" ind1=" " ind2=" ">
    <subfield code="a">122 p.</subfield>
    <subfield code="d">21 cm</subfield>
  </datafield>
  <datafield tag="225" ind1=" " ind2=" ">
    <subfield code="a">EMCDDA Risk Assessments</subfield>
    <subfield code="v">5</subfield>
  </datafield>
  <datafield tag="330" ind1=" " ind2=" ">
    <subfield code="a">Foreword. Abbreviations. Introduction. Chapter 1: Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs. Chapter 2: Council decision. Chapter 3: Europol-EMCDDA progress report on PMMA and PMA. Chapter 4: Review of the pharmacotoxicological data on PMMA. Chapter 5: Sociological and criminological evidence on the risks of PMMA. Chapter 6: Public health risks of PMMA - epidemiological evidence. References. Participants in the risk assessment process. Further reading.</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">PREVEN&#xC7;&#xC3;O DA TOXICODEPEND&#xCA;NCIA</subfield>
    <subfield code="9">103892</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">RELAT&#xD3;RIO</subfield>
    <subfield code="9">410454</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">DROGA SINT&#xC9;TICA</subfield>
    <subfield code="9">320915</subfield>
  </datafield>
  <datafield tag="606" ind1=" " ind2=" ">
    <subfield code="a">OEDT</subfield>
    <subfield code="9">321506</subfield>
  </datafield>
  <datafield tag="710" ind1=" " ind2=" ">
    <subfield code="a">EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION</subfield>
    <subfield code="9">351987</subfield>
  </datafield>
  <datafield tag="955" ind1=" " ind2=" ">
    <subfield code="x">Oferta</subfield>
  </datafield>
  <datafield tag="995" ind1=" " ind2=" ">
    <subfield code="1">0</subfield>
    <subfield code="4">PJ_19_000000000000000_D_81</subfield>
    <subfield code="5">2022-06-06</subfield>
    <subfield code="6">PJ28082</subfield>
    <subfield code="9">414200</subfield>
    <subfield code="a">PJ</subfield>
    <subfield code="c">PJ</subfield>
    <subfield code="f">PJ128082</subfield>
    <subfield code="k">PJ19.D.81</subfield>
    <subfield code="n">2022-06-06</subfield>
    <subfield code="o">0</subfield>
    <subfield code="r">MO</subfield>
    <subfield code="x">Oferta</subfield>
  </datafield>
</record>
